中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

44 records (took 0.024 seconds)

    METHODS FOR TREATING ATRIAL FIBRILLATION
    1.
    发明申请
    METHODS FOR TREATING ATRIAL FIBRILLATION 审中-公开
    治疗急性心肌梗死的方法

    公开(公告)号：US20110144199A1

    公开(公告)日：2011-06-16

    申请号：US12952696

    申请日：2010-11-23

    Applicant: Peter G. Milner ,  David Jack Ellis

    Inventor： Peter G. Milner ,  David Jack Ellis

    IPC: A61K31/343 ,  A61P9/00

    CPC classification number: A61K31/343

    Abstract: The subject invention provides methods for reducing atrial fibrillation (AF) episode duration, methods for reducing stroke rate, methods for increasing time in normal sinus rhythm (NSR), methods for preventing atrial remodeling, and methods for reversing atrial remodeling, all comprising administering an amount of budiodarone effective to reduce AF episode duration.

    Abstract translation: 本发明提供减少心房颤动（AF）发作持续时间的方法，降低卒中率的方法，增加正常窦性心律（NSR）时间的方法，预防心房重构的方法，以及逆转心房重构的方法，所有方法均包括给予 有效减少AF发作持续时间的剂量的量。

    METHODS FOR TREATING ATRIAL FIBRILLATION AND REDUCING STROKE RATE IN ATRIAL FIBRILLATION PATIENTS
    2.
    发明申请
    METHODS FOR TREATING ATRIAL FIBRILLATION AND REDUCING STROKE RATE IN ATRIAL FIBRILLATION PATIENTS 审中-公开
    治疗急性心肌梗死的方法和降低急性心肌梗死患者的卒中率

    公开(公告)号：US20110269762A1

    公开(公告)日：2011-11-03

    申请号：US12952666

    申请日：2010-11-23

    Applicant: Peter G. Milner ,  David Jack Ellis

    Inventor： Peter G. Milner ,  David Jack Ellis

    IPC: A61K31/5377 ,  A61K31/4439 ,  A61P25/00 ,  A61K31/343 ,  A61P9/00 ,  A61K31/437 ,  A61K31/352

    CPC classification number: A61K31/437 ,  A61K31/343 ,  A61K31/352 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

    Abstract: The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering budiodarone to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of budiodarone and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of budiodarone may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling. In some methods of the invention, budiodarone is administered 400 mg BID or more preferably 600 mg BID.

    Abstract translation: 本发明提供了降低卒中发生率的方法，用于预防心房重塑的方法，以及通过施用贝碘酮以减少心房颤动（AF）发作持续时间和抗凝血剂（AC）来逆转心房重塑的方法。 根据本发明的一些方法，平均AF发作持续时间可以减少到小于约24,5,3或1小时，并且最大AF发作持续时间可以减少到小于约20,10或5 小时。 根据本发明的一些方法，给予布洛诺酮和AC时降低的卒中率小于年龄调整后的总卒中率。 此外，一些方法提供可以治疗在给予他莫达酮之前对一种或多种抗心律失常药物难治的患者。 一些方法可用于预防心房重塑，另一些方法用于预防房颤重建，包括量化逆转心房重塑的方法。 在本发明的一些方法中，给予他达洛酮400mg BID或更优选600mg BID。

    METHODS FOR STROKE REDUCTION IN ATRIAL FIBRILLATION PATIENTS
    3.
    发明申请
    METHODS FOR STROKE REDUCTION IN ATRIAL FIBRILLATION PATIENTS 审中-公开
    方法减少ATRIAL FIBRILLATION患者

    公开(公告)号：US20110136779A1

    公开(公告)日：2011-06-09

    申请号：US12952683

    申请日：2010-11-23

    Applicant: Peter G. Milner ,  David Jack Ellis

    Inventor： Peter G. Milner ,  David Jack Ellis

    IPC: A61K31/397 ,  A61K31/40 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/444 ,  A61K31/4418 ,  A61K31/37 ,  A61K31/4402 ,  A61K31/445 ,  A61K31/439 ,  A61P9/00 ,  A61P7/02

    CPC classification number: A61K31/37 ,  A61K31/397 ,  A61K31/40 ,  A61K31/439 ,  A61K31/4402 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/5377

    Abstract: The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering a multiple ion channel blocker anti-arrhythmic to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of multiple ion channel blocker and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of the multiple ion channel blocker may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling. In some methods of the invention, budiodarone is administered 400 mg BID or more preferably 600 mg BID.

    Abstract translation: 本发明提供了降低卒中发生率的方法，用于预防心房重塑的方法，以及通过施用多重离子通道阻断剂抗心律不齐以减少心房颤动（AF）发作持续时间和抗凝血剂（AC）来逆转心房重构的方法。 根据本发明的一些方法，平均AF发作持续时间可以减少到小于约24,5,3或1小时，并且最大AF发作持续时间可以减少到小于约20,10或5 小时。 根据本发明的一些方法，施用多个离子通道阻滞剂和AC时降低的卒中率小于经年龄调整的总卒中率。 此外，一些方法提供了在给予多重离子通道阻断剂之前对一种或多种抗心律失常药物难治的患者也可以进行治疗。 一些方法可用于预防心房重塑，另一些方法用于预防房颤重建，包括量化逆转心房重塑的方法。 在本发明的一些方法中，给予他达洛酮400mg BID或更优选600mg BID。

    Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
    5.
    发明授权
    Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis 失效
    用于治疗糖尿病，高脂血症，高胆固醇血症和动脉粥样硬化的材料和方法

    公开(公告)号：US06768008B2

    公开(公告)日：2004-07-27

    申请号：US09961542

    申请日：2001-09-21

    Applicant: Pascal Druzgala ,  Peter G. Milner ,  Jurg R. Pfister

    Inventor： Pascal Druzgala ,  Peter G. Milner ,  Jurg R. Pfister

    IPC: C07D27734

    CPC classification number: C07D277/20 ,  C07D261/12 ,  C07D277/34 ,  C07D311/70 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07J3/00 ,  Y10S514/866

    Abstract: The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.

    Abstract translation: 本发明提供了可用于治疗II型糖尿病的药物化合物。 这些化合物是有利的，因为它们容易被代谢药物解毒系统代谢。 特别地，提供了被设计为在化合物的结构内包含酯的噻唑烷二酮类似物。 本发明还涉及治疗疾病如糖尿病的方法，其包括施用包含化合物的治疗有效组合物，所述化合物被设计为由血清或细胞内水解酶和酯酶代谢。 还教导了含酯的噻唑烷二酮类似物的药物组合物。

    Enantiomeric compounds for treatment of cardiac arrhythmias and methods of use
    6.
    发明授权
    Enantiomeric compounds for treatment of cardiac arrhythmias and methods of use 有权
    用于治疗心律失常的对映体化合物及其使用方法

    公开(公告)号：US06362223B1

    公开(公告)日：2002-03-26

    申请号：US09684046

    申请日：2000-10-06

    Applicant: Pascal Druzgala ,  Peter G. Milner

    Inventor： Pascal Druzgala ,  Peter G. Milner

    IPC: A61K31335

    CPC classification number: C07D307/54 ,  Y10S514/821

    Abstract: The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The enantiomerically purified compounds, and compositions of these compounds, exhibit unexpectedly distinct and advantageous characteristics, such as a markedly superior ability to reduce or inhibit ventricular premature beats, as compared to racemic mixtures of the compounds.

    Abstract translation: 本发明涉及新颖的对映异构体纯的化合物和包含该化合物的组合物，用于治疗心律失常。 本发明还涉及制备和纯化化合物的方法。 与化合物的外消旋混合物相比，对映异构体纯化的化合物和这些化合物的组合物显示出意想不到的和有利的特征，例如显着优异的降低或抑制心室过早搏动的能力。

    Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
    10.
    发明授权
    Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components 失效
    通过与血液成分缀合，保护内源性治疗肽免受肽酶活性的影响

    公开(公告)号：US07256253B2

    公开(公告)日：2007-08-14

    申请号：US11066697

    申请日：2005-02-25

    Applicant: Dominique P. Bridon ,  Alan M. Ezrin ,  Peter G. Milner ,  Darren L. Holmes ,  Karen Thibaudeau

    Inventor： Dominique P. Bridon ,  Alan M. Ezrin ,  Peter G. Milner ,  Darren L. Holmes ,  Karen Thibaudeau

    IPC: A61K38/00 ,  C07K14/00

    CPC classification number: C07K19/00

    Abstract: A secretin or secretin derivative protected against peptidase activity. The secretin or derivative comprises a peptidic sequence and a reactive group selected from the group consisting of succinimidyl and maleimido groups capable of reacting with an amino group, hydroxyl group or thiol group on a blood component to form a stable covalent bond. The reactive group is attached at a position along the peptidic sequence that provides, when conjugated to a blood component, a higher stability against peptidase degradation than the unconjugated secretin or derivative, and therefore an increased maintenance of the therapeutic activity compared to the unconjugated secretin or derivative. Such a compound is thus effective to provide a source of secretin having a high stability against peptidases. A method for synthesizing such a compound is also described.

    Abstract translation: 保护蛋白酶活性的促胰液素或促胰液素衍生物。 分泌素或衍生物包含肽类序列和选自能够与血液成分上的氨基，羟基或硫醇基反应形成稳定的共价键的琥珀酰亚胺基和马来酰亚胺基的反应性基团。 反应性基团连接在沿着肽序列的位置，当与血液成分缀合时，其比非共轭分泌素或衍生物具有比肽酶降解更高的稳定性，因此与未缀合的促胰液素相比，治疗活性的维持得到增加 衍生物。 因此，这样的化合物有效地提供对肽酶具有高稳定性的促胰液素来源。 还描述了合成这种化合物的方法。

Patent Agency Ranking